Form 4: Bolt Biotherapeutics COO Grant Yonehiro Acquires 155,000 Stock Options

Grant Yonehiro, Chief Operating Officer of Bolt Biotherapeutics, acquired 155,000 stock options on July 23, 2024, according to a Form 4 filing with the SEC.

Summary

• Grant Yonehiro, the Chief Operating Officer of Bolt Biotherapeutics, acquired 155,000 stock options on July 23, 2024.
• The exercise price of these options is $0.7301.
• The options vest monthly over three years, starting July 15, 2024, provided Yonehiro continuously provides services to the company.
• The options expire on July 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, suggesting confidence in the company's future, but without specific details to drive a higher positive score.

Positives

• The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements, but the vesting schedule implies a multi-year commitment from the COO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The vesting schedule of 1/36th per month is a typical vesting arrangement.
• Comparing the exercise price and the number of options granted to similar companies would provide a better understanding of the value of this grant.

Stakeholder Impact

• The stock option grant could incentivize the COO to improve company performance, potentially benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates